NCT07005921Completed
QEEG-NEUROFEEDBACK FOR COGNITIVE REHABILITATION IN LONG COVID-19 SURVIVORS WITH BRAIN FOG
QEEG-NEUROFEEDBACK FOR COGNITIVE REHABILITATION IN LONG COVID-19 SURVIVORS WITH BRAIN FOG: A Sham-controlled, Double-blind, Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
The pandemic has highlighted social, economic, educational, and political issues that have affected the health and quality of life of millions of Brazilians. Currently, attention and memory impairment remains predominant among the cognitive symptoms of Coronavirus observed in adults. The persistance of the reffered impairment after 12 weeks of COVID-19 is known as cognitive impairment in post-COVID-19 syndrome. Despite studies indicating the negative effects of COVID-19 on attention and memory, there is a gap in the literature regarding the investigation of QEEG-neurofeedback training (QEEG-NFT) efficacy for neurocognitive rehabilitation in COVID survivors with brain fog. In this context, quantitative electroencephalogram neurofeedback training (EEGq-NFT) is a promising non-invasive intervention designed to improve cognition, such as attention and working memory. By modifying electrophysiological patterns in the cerebral cortex. Considering the information presented, the question is what is the efficacy of EEGq-NFT training in rehabilitating attention and working memory in adults with cognitive impairment due to post-COVID-19 syndrome. This study aims to verify the efficacy of EEGq-NFT to rehabilitate cognition, more specifically attention, working memory and speed processing, in adults with cognitive impairment related to post-COVID-19 syndrome. A total of 40 participants were be randomly assigned to an EEGq neurofeedback training group (n = 13), an active control group called SHAM EEGq-neurofeedback (n = 13), and a waiting list control group (n = 14). The theta/beta ratio reduction protocol at frontal and central areas were used, with a total of 13 sessions. The Psychological Battery of Attention 2 (BPA-2), Digit Span Test (DST) and Five Digit Test (FDT) were employed to measure attention, working memory and speed processing levels. Statistical analyses were performed using JASP and R softwares with statistical significance set at p \< 0.05 for a 95% confidence interval. The research followed all ethical standards for studies involving human subjects and was submitted for review and approval at the Research Ethics Committee.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 3 Jun 2025
- Start date
- 10 Jun 2025
- Primary completion date
- 14 Aug 2026
- Lead sponsor
- Jade Carvalho Da Silva
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT07005921
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 10 Jun 2025 to the primary completion date, 14 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- The inclusion criteria were: 1) Present a history of positive diagnosis of COVID, 2) Present post-COVID-19 syndrome, as defined by the United Kingdom's National Institute for Health and Care Excellence (NICE), 3) Present a score equal or lower than 26 on the Montreal Cognitive Assessment (MoCA), 4) Be over 18 years old and under 60 years old, 5) Not use psychoactive substances, such as methylphenidate, benzodiazepines and hypnotics, 6) Not have a history of neurological and/or psychiatric diseases prior to or subsequent COVID-19, 7) Authorize participation in the study through the informed consent form. The exclusion criteria were: 1) Present physical or cognitive repercussions resulting from other diagnoses prior to or subsequent to COVID-19, 2) Discontinue participation in the study, 3) Present a history of attention and memory impairment prior to the diagnosis of COVID-19.
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Santos Dumont Institute Coordinator of this site? Confirm its status | Macaíba | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.